On November 25, 2024, Boston Scientific announced that it would acquire infusion pump manufacturer Intera Oncology for an undisclosed amount.

Intera Oncology has developed the Intera 3000 hepatic artery infusion pump and chemotherapy drug fluorouridine. Both have obtained FDA approval. This pump can be used for hepatic arterial infusion (HAI) therapy to treat liver tumors mainly caused by metastatic colorectal cancer. The Intera 3000 is the only approved constant current implantable pump for HAI treatment in the United States.

01. Only approved in the United States
Intera Oncology is a rapidly growing Boston life sciences company with a mission to change the course of cancer in patients with colorectal and cholangiocarcinoma. Founded by two doctors in 2019, their shared vision is to improve the survival rate of patients with colorectal cancer liver metastases and cholangiocarcinoma by ensuring access to hepatic arterial infusion (HAI) therapy.
Hepatic arterial infusion (HAI) therapy is a treatment method for colorectal cancer or cholangiocarcinoma (intrahepatic cholangiocarcinoma) that has spread to the liver. Traditional systemic chemotherapy typically involves intravenous delivery, requiring drugs to pass through the body's bloodstream to reach the liver. Only a small portion of chemotherapy drugs ultimately reach tumors in the liver. Through HAI therapy, drugs are delivered to the liver using the Intera 3000 HAI pump, which is implanted beneath the abdominal skin. Compared to systemic chemotherapy, this precise local delivery provides up to 400 times the drug concentration for tumors. The drug is administered directly to tumors in the liver through the hepatic artery, thereby limiting potential side effects in other areas.

The flagship product of Intera Oncology is the Intera 3000 hepatic artery infusion pump - a palm sized implantable device that delivers a continuous stream of chemotherapy directly to tumors in the liver through the hepatic artery. This allows patients to engage in normal daily activities outside the hospital during treatment with minimal disruption to their daily lives. The Intera 3000 is the only approved constant current implantable pump for HAI treatment in the United States.
The company expects to complete the transaction in the first half of 2025.

Peter Pattison, President of Interventional Oncology and Embolization at Boston Scientific, said, "Liver cancer is the leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease while minimizing systemic side effects and improving patient outcomes. Given technological advancements, positive clinical outcomes, and ongoing trials, the oncology community is increasingly interested in HAI therapy. We believe this acquisition will enable us to provide doctors and their patients with more comprehensive solutions for treating primary and metastatic liver cancer

02. Growth of 19.4%: Latest quarterly report
In the third quarter of 2024, Boston Scientific once again set a benchmark in the medical device industry with outstanding performance. Its revenue and profit have both achieved significant growth, demonstrating strong market competitiveness and sustained innovation capabilities.

 Double harvest of income and profit, annual guidance raised
According to the financial report, Boston Scientific's third quarter revenue reached $4.21 billion, a year-on-year increase of 19.4%, which far exceeded market expectations. Thanks to the strong expansion of the cardiovascular department and excellent performance in areas such as neural regulation and urology, the company's adjusted earnings per share (EPS) also reached $0.63, higher than the market estimate of $0.59. Based on this, Boston Scientific management has raised its full year revenue guidance, expecting sales to increase by 16.5% and earnings per share to remain stable between $2.45 and $2.47.

 Cardiovascular Business: Technological Innovation Drives High Growth
The cardiovascular business continues to be the core growth engine of Boston Scientific, with net sales increasing by 29.2% year-on-year in the third quarter. Among them, the global sales of interventional heart disease therapy increased by 13.4%, and the agent ™ Hot selling and AVVIGO in the US market ™+ The global promotion of the platform is indispensable. The field of structural heart valves has also achieved double-digit growth, mainly driven by ACURATE Neo2 ™ Driven by leading performance in the European market. In addition, global sales of WATCHMAN left atrial appendage occluder increased by 17.8%, especially in the US and Japanese markets, where WATCHMAN FLX ™ Pro The gradual promotion of the product has further improved performance. The cardiac rhythm management business has also achieved steady growth, with particularly outstanding performance in the field of electrophysiology, with global net sales increasing by as much as 177% year-on-year. FARAPULSE ™ The widespread application of equipment is its main driving force. The peripheral intervention business also performed well, with global net sales increasing by 11.8%.

 The medical surgery department is steadily growing and making efforts in multiple fields
In addition to the cardiovascular field, Boston Scientific's MedSurg department has also achieved stable growth. Global sales of endoscope business increased by 7.8%, thanks to AXIOS ™ And Exalt D ™ Waiting for strong performance of core products. Urology health business increased by 10.3% year-on-year, Rezum ™ And SpaceEAR ™ Products have become the main driving force for growth. The neural regulation business also achieved a growth of 17.0%, with excellent performance in brain implants and pain management business.

03. Frequent merger and acquisition activities, accelerating layout
Against the backdrop of continuous transformation in the medical technology industry, Boston Scientific has once again demonstrated its activity and strategic vision in the industry through its frequent merger and acquisition activities. Recently, the company has completed multiple important acquisitions, further consolidating and expanding its leading position in medical devices and technology.

In just the past few months, Boston Scientific has successfully acquired Axonics and Silk Road Medical, and reached an acquisition agreement for Cortex, a developer of cardiac mapping technology. These mergers and acquisitions not only enrich Boston Scientific's product line, but also bring it more technological innovation and market opportunities.

As early as September 2023, Boston Scientific clearly stated the core role of mergers and acquisitions in its overall business plan. The company believes that mergers and acquisitions can quickly acquire new technologies, products, and market share, thereby accelerating the company's growth and transformation. This strategic idea was fully reflected in the subsequent merger and acquisition activities.

It is worth mentioning that Boston Scientific announced the acquisition of Relief Medsystems in 2023 and successfully completed the transaction in November. This acquisition further enhances the company's strength in pain management and lays a solid foundation for future market expansion.

Looking back at the past few years, the pace of mergers and acquisitions by Boston Scientific has never stopped. At the end of 2022, the company acquired a majority stake in Acotec for approximately $523 million, marking a significant breakthrough in surgical suture technology. Entering 2023, Boston Scientific continues to increase its M&A efforts and completed the acquisition of Apollo Endosurgery for $615 million in April, further enhancing its competitiveness in the endoscopic surgery field.

In addition, Boston Scientific has successfully acquired high-quality companies such as Farapulse, Baylis Medical, and Lumenis. These mergers and acquisitions not only enrich the company's product line and technological reserves, but also add more chips to its competition in the global medical technology market.

As a company with a strong background in biomedical engineering, Boston Scientific understands the importance of technological innovation and market expansion. Therefore, the company continuously integrates industry resources and enhances its own strength through frequent mergers and acquisitions, in order to occupy a more important position in the future medical technology market.

Source: http://qixieke.com/Font/index/detailPage.html?id=3267-142